Pertuzumab Plus Trastuzumab for Biliary Tract Cancer With ERBB2/3 Alterations
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Pertuzumab Plus Trastuzumab in Patients With Biliary Tract Cancer With ERBB2/3 Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study
J. Clin. Oncol 2024 May 15;[EPub Ahead of Print], TL Cannon, M Rothe, PK Mangat, E Garrett-Mayer, VK Chiu, J Hwang, N Vijayvergia, OB Alese, EG Dib, HL Duvivier, KA Klute, V Sahai, ER Ahn, P Bedano, D Behl, S Sinclair, R Thota, WJ Urba, ES Yang, GN Grantham, DC Hinshaw, A Gregory, S Halabi, RL SchilskyFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.